| All (N=45) | Pancreatic (N=19) | Gastrointestinal intestinal and unknown origin (N=17) | Others lung and paraganglioma (N=9) |
---|---|---|---|---|
Sex | Â | Â | Â | Â |
Male | 32 (71.1) | 15 (78.9) | 9 (52.9) | 8 (88.9) |
Female | 13 (28.9) | 4 (21.1) | 8 (47.1) | 1 (11.1) |
Age (yrs) | Â | Â | Â | Â |
Median (range) | 52 (28-73) | Â | Â | Â |
ECOG performance status | Â | Â | Â | Â |
0 | 36 (80.0) | 13 (68.4) | 17 (100) | 6 (66.7) |
1 | 6 (13.3) | 3 (15.8) | -- | 3 (33.3) |
2 | 3 (6.7) | 3 (15.8) | Â | Â |
Ki67 index | Â | Â | Â | Â |
≤2 | 10 (25.6) | 2 (11.8) | 5 (33.3) | 3 (42.8) |
3-20 | 29 (74.4) | 15 (88.2) | 15 (66.6) | 4 (57.2) |
Missing | 6 | 2 | 2 | 2 |
Octreoscan | Â | Â | Â | Â |
Positive | 43 (95.6) | 18 (94.7) | 16 (94.1) | 9 (100) |
Negative | 2 (4.4) | 1 (5.3) | 1 (5.9) | Â |
Circulating chromogranin A | Â | Â | Â | Â |
Normal | 8 | 3 (17.6) | 4 (23.5) | 1 (12.5) |
Elevated | 34 | 14 (82.4) | 13 (76.5) | 7 (87.5) |
Missing | 3 | 2 | -- | 1 |
Sites of metastatic disease | Â | Â | Â | Â |
Liver | 41 (91.1) | 18 (94.7) | 16 (94.1) | 7 (77.8) |
Lymph nodes | 17 (37.8) | 6 (31.4) | 8 (47.1) | 3 (33.3) |
Lung | 5 (11.1) | 0 (0) | -- | 4 (44.4) |
Bone | 2 (4.4) | 2 (10.5) | 1 (5.9) | -- |
Syndrome | 17 (37.8) | 5 (26.3) | 11 (64.7) | 1 (11.1) |
Diarrhea | 10 (22.2) | 3 (15.8) | 6 (35.3) | 1 (11.1) |
Hot flashes | 7 (15.6) | -- | 6 (35.3) | 1 (11.1) |
Rash | 7 (15.6) | -- | 6 (35.3) | 1 (11.1) |
Hypoglycemia | 1 (2.2) | 1 (5.3) | -- | -- |
Cushing’s syndrome | 1 (2.2) | 1 (5.3) | -- | -- |
Previous treatments | Â | Â | Â | Â |
Surgery | 34 (75.6) | 13 (68.4) | 14 (82.3) | 7 (77.8) |
Radiotherapy | 2 (4.4) | 2 (10.5) | -- | -- |
Radionuclide therapy with somatostatin analogues | 23 (51.1) | 10 (43.5) | 8 (34.8) | 5 (21.7) |